Eli Lilly and Company (NYSE:LLY) Price Target Raised to $1,285.00 at Deutsche Bank Aktiengesellschaft

Eli Lilly and Company (NYSE:LLY) had its price target increased by Deutsche Bank Aktiengesellschaft from $1,200.00 to $1,285.00 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft’s price objective indicates a potential upside of 21.56% from the stock’s current price.

A number of other brokerages have also issued reports on LLY. Wells Fargo & Company raised their price target on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a research note on Thursday. Wolfe Research raised their target price on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. Guggenheim lowered their target price on shares of Eli Lilly and Company from $1,163.00 to $1,161.00 and set a “buy” rating for the company in a report on Tuesday, January 20th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Eli Lilly and Company in a research note on Monday, December 22nd. Finally, Berenberg Bank boosted their price objective on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a research note on Tuesday, December 2nd. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,207.29.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,057.10 on Monday. The company has a market capitalization of $999.36 billion, a price-to-earnings ratio of 46.06, a PEG ratio of 0.91 and a beta of 0.39. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The company’s 50 day simple moving average is $1,052.25 and its 200 day simple moving average is $899.78.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 112.50% and a net margin of 31.66%.The company had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. During the same period in the previous year, the firm posted $5.32 EPS. Eli Lilly and Company’s revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Institutional Trading of Eli Lilly and Company

Large investors have recently added to or reduced their stakes in the stock. Maryland Capital Advisors Inc. acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth approximately $25,000. Sumitomo Mitsui Financial Group Inc. bought a new position in Eli Lilly and Company during the 2nd quarter valued at $27,000. Vermillion & White Wealth Management Group LLC grew its holdings in Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after acquiring an additional 16 shares in the last quarter. Evolution Wealth Management Inc. bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth about $29,000. Finally, Steph & Co. raised its stake in shares of Eli Lilly and Company by 290.0% in the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after purchasing an additional 29 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to acquire Orna Therapeutics to add an in‑vivo CAR‑T and genetic‑medicine platform that could expand long‑term pipeline optionality in autoimmune and cell‑therapy areas. Lilly to acquire Orna Therapeutics
• Positive Sentiment: Strategic partnership with Innovent Biologics (large global oncology/immunology pact reported at ~US$8.85B) expands Lilly’s China and emerging‑market collaboration footprint and boosts oncology growth optionality. Innovent Biologics Strikes Partnership Deal With Eli Lilly
• Positive Sentiment: Management reinforced “hyper‑growth” momentum on the Q4 earnings call after a revenue and EPS beat and raised FY guidance — supporting the market’s bullish growth outlook for GLP‑1 and new launches. Eli Lilly Earnings Call Highlights Hyper-Growth Momentum
• Positive Sentiment: Analyst actions are supportive — Leerink raised its price target and Goldman Sachs reaffirmed a Buy with an elevated growth thesis, signaling continued institutional conviction. Leerink Partners adjusts price target on Eli Lilly
• Positive Sentiment: Regulatory moves cracking down on compounded GLP‑1s are viewed as a tailwind for Lilly’s branded obesity/diabetes franchise, reducing a lower‑priced competitor channel. FDA Crackdown on Compounded GLP-1s Strengthens Eli Lilly’s Franchise
• Positive Sentiment: Infrastructure and hiring: a new college lab and Lilly’s planned $3.5B Lehigh Valley plant support manufacturing scale for GLP‑1 production and local workforce development. College’s new lab will train workers for Eli Lilly’s planned $3.5B facility
• Neutral Sentiment: Market commentary highlights pricing pressure risk: some reports note U.S. GLP‑1 price declines and competitive dynamics that could temper longer‑term revenue assumptions. Analysts Project Eli Lilly to Deliver 21%+ Revenue Growth
• Neutral Sentiment: An institutional investor (Bristol Gate Capital) trimmed its LLY stake — a common portfolio rebalancing move but one that can add short‑term supply. Bristol Gate Capital Partners Trims Eli Lilly Stake

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.